Successful Management of a Severe Case of Bisphosphonates Related Osteonecrosis of the Jaw in a Multiple Myeloma Patient by Luchetti, César Gabriel et al.
JIACD Continuing Education 
Successful Management of a Severe Case 
of Bisphosphonate Related Osteonecrosis 
of the Jaw in a Multiple Myeloma Patient 
Cesar Luchetti, DDS, MS1 • Sebastian Yantorno, MD2 • Julian Barrales, MD3 
Juan Napal, MD4 • Jorge Milone, MD, PhD5 • Alicia Kitrilakis, DOS, PhD6 
Abstract 
Background: Bisphosphonate-related osteone-
crosis of the jaw (BRONJ) is a serious oral 
complication of bisphosphonate treatment 
involving the exposure of necrotic maxillary or 
mandibular bona. BRONJ is associated with 
pain, paresthesia, and oral dysfunction gen· 
erating an impairment of the quality of life. 
Treatment of this complication remains diffi· 
cult and the most useful action is prevention. 
Case Report: This is a case report of a multiple 
myeloma patient whose first signa of BRONJ 
bagan in 2002 with the development of an 
aggressive bilateral osteonecrosis of the man· 
dible. Successful management of this case is 
described with 17 months of follow up monitoring. 
Conclusions: This case supports the concept that 
BRONJ may be successfully treated. The approach 
described to treat this case, especially regarding 
sequestrum management, could minimize the sur· 
gical corrections after the sequestrum is removed. 
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Learning Objectives 
After reading this article, the reader should be 
able to: 
1. Discuss Bisphosphonate Related Osteone-
crosis of the Jaw (B RONJ)and its causes. 
2. Understand how to diagnosis and manage 
BRONJ 
3. Understand the surgical and 
pharmocological management of BRONJ 
INTRODUCTION 
Bisphosphonates, a class of drugs that inhibit 
bone resorption, were widely developed over the 
last four decades starting with the work of Herbert 
Fleish, who published the first report in 1968.1 To 
date, the main use of the drug was for the pre-
vention and treatment of osteoporosis and other 
bone metabolism diseases, based on their ability 
to decrease bone tumover trough the inhibition 
of osteoclast differentiation and a decrease in 
its activity and survival rate.2 Recently, bisphos-
phonate use was extended to treat oncological 
diseases which present bone affectation such 
multiple myeloma and bone metastasis, in order to 
lower the skeletal effects. First studies are dated 
at the beginning of the nineties,8 being today 
a very important component of the therapeu-
tic approach in these conditions. 4 However, by 
the end of 2003, a new and a challenging entity 
developed as a complication in patients treated 
with bisphosphonates was described mainly 
associated with Pamidronate and Zoledronic 
Acid.6•8 Bisphosphonate-related osteonecro-
sis of the jaw (B RONJ) is a serious oral compli-
cation of bisphosphonate treatment involving 
the exposure of necrotic maxillary or mandibular 
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FiguNt 1: Non-healing sockets after extractions in 
December 2002. 
bone, occurring in 1 .8 to 1 2.8 o/o of the cases 
with intravenous bisphosphonates administration.7 
CASE DESCRIPTION 
A 48 year old white, male patient was referred to 
the Department of lmplant Dentistry at the National 
University of La Plata. (Universidad Nacional de 
La Plata) in La Plata, Buenos Aires, Argentina in 
December 2005. The patient was undergoing 
treatment far multiple myeloma. The patient was 
diagnosed with multiple myeloma, lgG monoclo-
nal band in proteinogram, in June 1996. Upan 
diagnosis of multiple myeloma, the patient was ini-
tially treated with four cycles of the "VAD proto· 
col" (vincristine, adriamycin and dexamethasone) 
and autologous bone marrow transplantation in 
May 1997. Maintenance was accomplished with 
interferon until 2000, and later thalidomide until 
2002. Concomitant treatments with bisphospho-
nates were pamidronate from September 2001 to 
December 2001 and zoledronic acid from Janu-
ary 2002 to December 2005. The patient expe-
rienced a relapse in 2006 and bortezomib was 
used for B cycles. The patient has since experi-
Figure 2: Control radlograph In March 2003 showed no 
improvements. 
Figure 4: Patlent lost an addltlonal tooth, number 31 In 
March 2004 and boy sequestrums began to form. 
Figure 6: First contad with the patient in December 2005. 
Extenslve bllateral bone exposure Is noted. 
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Figure J: In September 2003, patlent lost teeth 1 S. 20, 
and29. 
Figure 5: Control x-ray In December 2004 showed the 
lfmlts of the affected bone. 
Figure 7: Radiograph showing the status of the affected 
bone In December 2005. 
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Figura 8: Clinical situation in September 2006, without 
changes. 
Figure 10: Computer tomography sean showlng the 
extension ofthe lesions. 
enced complete remission following this treatment. 
In 2002, the patient had some routine den-
tal extractions which never fully healed and 
resulted in chronically exposed bone. Suspect-
ing myeloma dissemination to the mandible, the 
oral surgeon at that time took a biopsy sample. 
The condition now known as BRONJ was not yet 
known at that time (figure 1 ). A few months later, 
the condition became increasingly aggrivated, 
with the consequent loss of more teeth and a 
progressive affectation to the bone (figures 2-5). 
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Figura 9: Radiograph taken in November 2006 showing a 
progresslon of the affected bone. 
The patient was first seen in our department 
in December 2005 and presentad with signifi-
cant bilateral bone exposure in the mandible (fig-
ures 6,7). According to the recommendations at 
the time, our approach was to try to maintain the 
exposed bone as clean as possible to prevent fur-
ther infection. Our treatment consisted of long 
term antibiotics (Amoxicillin plus clavulanic acid, 1 
gr, twice a day and metronidazole 500 mg twice a 
day), local rinses with clorhexidine 0.1 2 % 3 times 
a day, and rinses with 3% hydrogen peroxide once 
a day. After nine months of this conservativa treat-
ment, the patient showed no improvement. Addi-
tionally, the exposed bone in the right side of the 
mandible began to form a sequestrum and loasen 
(figures 8-1 O). At this time, the patient asked for 
a solution to his problem. We explained the risks 
and our approach based in the management of 
previous smaller cases. Following our discussions 
of the risk and benefits of treatment, the patient 
agreed to proceed. As such, our treatment pro-
tocol for this patient was modified as follows. 
We started to manipulate the bony seques-
trum by gently trying to loosen it three times a 
Figure 11 : Cllnlcal sltuadon after removlng the 
sequestrum on the ñght side in December 2006. 
Figure 13: Histology showlng necrotic bon~ wtth empty 
lacunaes and associated infeded tissue. (H&E stain. 
magnlficatlon x 100) 
week. During each visit, we carefully irrigated and 
cleansed the area apical to the sequestrum. To 
accomplish such, we used 5cc of clorhexidine 
0.12% followed by 5cc of 3% hydrogen perox-
ide. Detritus were eliminated by means of a hand 
brush and finally, an additional two irrigations 
with clorhexidine and hydrogen peroxide were 
perfonned. After a couple of weeks the seques-
trum was loose enough to attempt removal. We 
successfully removed the sequestrum with ron-
geurs and used rotary instrumenta to eliminate 
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Figure 12: Sequestrum removed. 
Flgun 14: Gram stalnlng demonstrated Gram (+) baclllus. 
(magnlfication x 100) 
remaining bony spicules to get a smooth bone 
surface and facilitate healing (figures 11, 1 2). 
The sequestrum was submitted far histo-
logic examination which revealed necrotic bone 
with empty lacunaes and associated infected 
tissue. With gram staining, Gram (+) bacil· 
lus were identified (figures 13, 14). Fifteen 
days following surgery, the soft tissue heal· 
ing looked acceptable and at one month, com-
plete healing of the surgical site was observed 
(figure 15). Having achieved this, we decided 
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Figure 15: Cllnlcal situatlon one month after sequestrum 
removal. 
Figure 11: Removal of the first part of the left sequestrum 
in February 2007. 
Figura 17: Clinical situation after removal ofthe remaining 
part of the left sequestrum. 
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Figure 18: Radiograph in July 2007. 
to proceed in the same fashion on the left side. 
Bone sequestrum on the left side presentad 
as two parts, first from the buccal and a few 
months later from the lingual {figures 16, 17). 
After two months, the tissues at the surgical 
sites were stable. Radiographic examination did 
not reveal formation of additional bone seques-
trum. We also performed a Serum e-terminal 
telopeptide (CTX) test according to the Marx pro-
tocol8 and got a result of 130 pg/ml, compatible 
with a moderate risk (figure 18). We then fabri-
cated and delivered a maxillary dental prosthe-
sis to give the patient the possibility to return to 
normal function, both masticatory and aesthetics 
wise, after several years (figures 19-21). Sev-
enteen months later, the previously affected tis-
sues continue to appear stable (figure 22). 
DISCUSSION 
Bisphosphonate s associated osteonecrosis of 
the jaw was first described in late 2003 and early 
2004.6•6 At this time, surgery was almost totally 
contraindicated in theses cases because of the 
probability of aggravating the condition. The usual 
recommendation was, and still applies, to main-
Figure 19: Removable prosthesls. 
tain the exposed bona ímection iree ana 1c have 
in mind that the patient c~n livc with some bone 
exposure without further problems.e.10 However1 as 
we demonstrated in this case, the infection of the 
bone can worsen, no matter how great the effort 
to provide minimally invasive palliative treatment. 
Our thought is that once the lesion affects the 
cortical plate and the medullary bone becomes 
exposed, adequate cleansing of the area seems to 
be more difficult and the infection control requires 
extreme care, both home and professional. Clor-
hexidine is the antiseptic of choice cited in most 
articles.8•1º We also like to use 3% hydrogen 
peroxide basad on our experience in managing 
abscess lesiona in soft tissues which are usually 
present in the limits of the exposed bone. Also, 
3% hydrogen peroxide can help in cases where 
the exposed bona presents a rough surface in 
which anaerobic bacteria could grow. Micro-
biological identification is important adjunct to 
aid infection management. Cultures must be 
made to search for aerobic and anaerobic bac-
teria, and also for fungus. Fungus can be pres-
ent as a result of many situations, with the most 
common being systemic immunity impairment 
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Figure 20: Removable prosthesls. 
Figure Z1: Removable prosthesls. 
Figure 2Z: Cllnlcal sltuatlon In December 2008, showlng 
stability of the soft tissues. 
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and the previous use of long terrn antibiotics. 
More recently, surgical approaches have 
been described in arder to achieve soft tissue 
healing in certain cases. Common features of 
these approaches are: 1} conservative resec-
tion of the necrotic bone with attempts at abtain-
ing a smooth surface; 2) use of platelet derivad 
growth factors; 3) tension free primary wound 
closue.11•12 We have used these approaches, 
especially with the use af platelet derived growth 
factor (PDGF), both far prevention in tooth extrac-
tions in compromised patients and for treatment 
of BRONJ. In cases where a bony sequestrum 
is present, it may be beneficia! to loasen them in 
steps rather than remove them in a single attempt. 
With proper homecare involving the patient irri-
gating below the sequestrum, this conservative 
approach may lead to initial healing of the over-
lying soft tissue, which could minimiza surgi-
cal corrections upon removal of the sequestrum. 
The serum e-terminal telopeptide (CTX) test8 
is currently recommended as a way to mea-
sure the risks of development and progression 
af BRONJ. When used together with imaging, 
clinical examination, and other complementary 
studies, CTX testing may prove to be a valu-
able adjunct in the decision process for treat-
ing patients at risk for or currently affected by 
BRONJ. The patient treated in this case report 
had moderate CTX levels and proceeded to 
heal without complication. Whether this heal-
ing was a result of the CTX values or the treat-
ment rendered cannot be determinad at this time. 
CONCLUSIONS 
The latest literature, and also this case, sup-
ports the concept that BRONJ may be success-
fully treated in the short term. The approach 
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described to treat this case, especially regard-
ing sequestrum management, could minimiza 
necessary surgical corrections upan removal of 
the sequestrum. However, the resolution of this 
particular case does nat ensure that every case 
can be resolved in the same way ar with the 
same results, but shows us that there is a real 
possibility to treat this pathology with success. 
Each case must be evaluated individually and 
primary approaches must always be conserva-
tive and focused on prevention. Additional stud-
ies on the development, diagnosis, prevention, 
and management of BRONJ are warranted. • 
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